Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple myeloma (MM)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519353-11-00

Enrollment

Registered

2024-12-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

Primary: Proportion of participants diagnosed with intermediate or high risk SMM that have MRD negativity three year from study enrollment

Detailed description

Clinical response by IMWG, Clinical outcomes by IMWG, Safety, Correlation with correlative and clinical outcomes

Interventions

DRUGDexametason Abcur 4 mg töflur

DRUGKyprolis 60 mg powder for solution for infusion

DRUGRevlimid 5 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Primary: Proportion of participants diagnosed with intermediate or high risk SMM that have MRD negativity three year from study enrollment	—

Secondary

Measure	Time frame
Clinical response by IMWG, Clinical outcomes by IMWG, Safety, Correlation with correlative and clinical outcomes	—

Countries

Iceland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026